Hidradenitis Suppurativa Clinical Trial
Official title:
Mindfulness in Hidradenitis Suppurativa
NCT number | NCT06123429 |
Other study ID # | 276379 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 3, 2023 |
Est. completion date | April 1, 2024 |
The study will investigate the impact of an 8-week-long Mindfulness-Based Stress Reduction course on quality of life and disease severity in patients with hidradenitis suppurativa (HS).
Status | Recruiting |
Enrollment | 30 |
Est. completion date | April 1, 2024 |
Est. primary completion date | April 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - This study will only enroll subjects between the ages of 18-years and 89-years of age. - Diagnosis of HS - Able to read and comprehend study materials in English, ie: surveys Exclusion Criteria: - Those who do not fit inclusion criteria - Non-English speaking - Patient who recently began any psychotropic medication within 3 months prior to the baseline evaluation visit. |
Country | Name | City | State |
---|---|---|---|
United States | UAMS Dermatology Clinic | Little Rock | Arkansas |
Lead Sponsor | Collaborator |
---|---|
University of Arkansas |
United States,
Kishimoto S, Watanabe N, Yamamoto Y, Imai T, Aida R, Germer C, Tamagawa-Mineoka R, Shimizu R, Hickman S, Nakayama Y, Etoh T, Sahker E, Carnie MB, Furukawa TA. Efficacy of Integrated Online Mindfulness and Self-compassion Training for Adults With Atopic De — View Citation
Kouris A, Platsidaki E, Christodoulou C, Efstathiou V, Dessinioti C, Tzanetakou V, Korkoliakou P, Zisimou C, Antoniou C, Kontochristopoulos G. Quality of Life and Psychosocial Implications in Patients with Hidradenitis Suppurativa. Dermatology. 2016;232(6):687-691. doi: 10.1159/000453355. Epub 2017 Jan 5. — View Citation
Vekic DA, Frew J, Cains GD. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. Australas J Dermatol. 2018 Nov;59(4):267-277. doi: 10.1111/ajd.12770. Epub 2018 Jan 21. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dermatology Quality of Life Index (DLQI scores) | Change in DLQI scores before and after Mindfulness Based Stress Reduction course.
DLQI score interpretation: 0 - 1 no effect at all on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life |
Week 1 of 8 week MBSR course intervention; Week 4; End of MBSR Course at week 8; and Week 12. | |
Primary | Generalized Anxiety Disorder (GAD7) | Change in GAD7 scores before and after Mindfulness Based Stress Reduction course. This is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." GAD-7 total score for the seven items ranges from 0 to 21. 0-4: minimal anxiety 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety | Week 1 of 8 week MBSR course intervention; Week 4; End of MBSR Course at week 8; and Week 12. | |
Primary | Patient Health Questionaire (PHQ9) | Change in PHQ9 scores before and after Mindfulness-Based Stress Reduction course.
Scoring: add up all checked boxes on PHQ-9 For every 3 Not at all = 0; Several days = 1; More than half the days = 2; Nearly every day = 3 Interpretation of Total Score Total Score Depression Severity 1-4 Minimal depression 5-9 Mild depression 10-14 Moderate depression 15-19 Moderately severe depression 20-27 Severe depression |
Week 1 of 8 week MBSR course intervention; Week 4; End of MBSR Course at week 8; and Week 12. | |
Secondary | Hidradenitis Suppurativa Quality of Life Index (HiSQOL) | Change in HiSQOL scores before and after Mindfulness-Based Stress Reduction course.
Grading: Not at all = 0 points Slightly = 1 point Moderately = 2 points Very much = 3 points Extremely = 4 points 0-17 = No effect 18-34 = Small effect 35-51 = Moderate effect 52-68 = Severe effect Max score = 68 points |
Week 1 of 8 week MBSR course intervention; Week 4; End of MBSR Course at week 8; and Week 12. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02904902 -
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
|
Phase 3 | |
Completed |
NCT03628924 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 2 | |
Not yet recruiting |
NCT05531747 -
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
|
N/A | |
Recruiting |
NCT06028230 -
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
Completed |
NCT03275870 -
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
Completed |
NCT03248531 -
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
|
Phase 2 | |
Withdrawn |
NCT04100083 -
Spironolactone for Hidradenitis Suppurativa
|
Phase 4 | |
Completed |
NCT00329823 -
Etanercept in Hidradenitis Suppurativa
|
Phase 2 | |
Recruiting |
NCT05710393 -
Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
|
||
Completed |
NCT04019041 -
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
|
Phase 2 | |
Completed |
NCT05286567 -
A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.
|
Phase 1 | |
Withdrawn |
NCT03929835 -
Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
|
Phase 2 | |
Terminated |
NCT04325607 -
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
|
N/A | |
Terminated |
NCT03238469 -
Microwave Ablation in Mild Axillary Hidradenitis Suppurativa
|
N/A | |
Completed |
NCT04449354 -
HidraWear AX HS Study
|
N/A | |
Recruiting |
NCT05934825 -
Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT06046729 -
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 | |
Completed |
NCT01516749 -
Anakinra as a Treatment for Hydradenitis Suppurativa
|
Phase 2 |